Hyperosmolar sodium lactate

PreclinicalSmall molecule

IInnogene Kalbiotech Pte. Ltd

Hyperosmolar sodium lactate is one of 3 small molecule programs targeting Trauma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TraumaCompleted

TraumaPreclinical

Completed

Competition

Competitive Landscape

3 competitors in Trauma

#DrugCompanyPhaseTrials

Sufenta

LLeaf Vertical Inc.

Phase 3

1 2

Penthrane

PPurdue Pharma, Canada

Preclinical

1 3

Hyperosmolar sodium lactate

IInnogene Kalbiotech Pte. Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hemorrhagic Shock1 trial

Efficacy, Safety of Solution Containing Hyperosmolar Sodium Lactate Infusion for Resuscitation of Patients With Hemorrhagic Shock

Completed·IInnogene Kalbiotech Pte. Ltd·Phase 3·NCT01433276·71 enrolled

Trauma1 trial

Effect of Exogenous Lactate on Neurocognitive in Brain Trauma

Completed·UUniversitas Padjadjaran·N/A·NCT01455376·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Hyperosmolar sodium lactate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyperosmolar sodium lactate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyperosmolar sodium lactate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Innogene Kalbiotech Pte. Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInnogene Kalbiotech Pte. Ltd

Hyperosmolar sodium lactate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hemorrhagic Shock1 trial

Trauma1 trial

References

Drug Info

Quick Facts

Related News